Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07660783 · ClinicalTrials.gov registry record · Phase 2
Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT07660783 is a Phase 2 study that has not yet begun recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT07660783, a Phase 2 study, has not yet begun recruiting, sponsored by Fred Hutchinson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant diseases requiring hematopoietic cell transplantation. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.
Interventions
- BIOLOGICAL ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-09 |
| Est. Completion | 2035-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07660783
The ClinicalTrials.gov registry entry for NCT07660783 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs is the first listed.
NCT07660783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07660783 about?
NCT07660783 is a clinical study titled "Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases". This phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant diseases requiring hematopoietic cell transplantation. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell t...
What is the current status of trial NCT07660783?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-09. Estimated completion is 2035-09.
What interventions are being tested in trial NCT07660783?
The interventions under investigation include: ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT07660783?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.